AMIPAQUE 6.75G

V08AB01(WHO) 2-({3-(Acetylamino)-5-[acetyl(methyl)amino]-2,4,6-triiodobenzoyl}amino)-2-deoxy-D-glucopyranose 31112-62-6Y 443944 DB01578Y 391998N RHH3W8F1CO D01311 ChEMBL1200889N DTXSID1023310 Metrizamideis anon-ioniciodine-basedradiocontrast agent.It is also a density gradient medium for thecentrifugationof biological particles. Historically metrizamide replaced bothiodized oil(trade names: Ethiodol, Lipiodol) andiofendylate(trade names: Pantopaque, Myodil) as thecontrast agentof choice formyelography(anX-ray studyof the spine now largely replaced byMRI). The radio opacity characteristics are such that finer detail is displayed with metrizamide, as well as the advantage of reabsorption from spinal fluid and excretion from the body – since unlike iofendylate, metrizamide is a water-soluble substance. All three agents are administered bylumbar puncture(also referred to as a spinal tap or cisternal puncture), at the cervicocranial junction. The human patient is rolled from thelateral decubitus(lying on the side) to prone. Ankles are strapped to the end of a hard X-ray,CT, or MRI table. To obtain images of thecervical regionthe patient is then carefully tilted in theTrendelenberg position(head down) so the contrast agent (particularly iofendylate) can enter the neck region. Care is given to prevent spilling dye into theposterior cranial fossa(back of the head) or to enter the cranial cavity in general. This speaks to the inability to remove the heavier or more viscous iofendylate without aspirating it withspinal fluidthrough a lumbar puncture needle in the low back (sticking up vertically) or back of the neck. Removal of iofendylate is necessary since it is not water-soluble. With metrizamide the issue is that if entering thecranial cavityand high dose exposure to theblood brain barrier, side effects are more likely encountered. Issues related to absorption into the general circulation are also encountered.